Irritable Bowel Syndrome (IBS) Diagnostics Market worth US $ 3,117.79 million by 2028 at a CAGR of 4.7% globally, COVID-19 impact and analysis by The Insight Partners

NEW YORK, September 17, 2021 / PRNewswire / – According to a new research study on “Irritable Bowel Syndrome (IBS) Diagnosis Market to 2027 – Global Analysis and Forecast – By Diagnosis and Indication ‘the market is expected to reach US $ 3,880.91 million in 2028 US $ 2,470.61 million in 2020. The market is expected to grow at a CAGR of 5.9% from 2021 to 2028. The growth of the market can be attributed to factors such as the increasing prevalence of Irritable Bowel Syndrome and related conditions and the increasing number of FDA approvals and diagnostic developments. On the other hand, challenges in diagnosing IBS such as lack of specific treatment which treat all symptoms are likely to restrain the growth of the market during the forecast period.


In 2021, North America dominated the global irritable bowel syndrome (IBS) diagnostics market. Market growth is driven by factors such as increased adoption of Irritable Bowel Syndrome (IBS) diagnostics in the United States, increased public health awareness, increased government strategic activities and the presence of leading players. .

Get Detailed Details About Irritable Bowel Syndrome Diagnosis Market (Number of Pages – 185, Number of Tables, Charts & Figures – 186)
Download the PDF brochure:

Asia Pacific is expected to be the fastest growing region. The market in Asia Pacific is expected to grow at a faster rate, due to the increasing prevalence of gastrointestinal disorders in countries such as Australia and India. In addition, the increase in product approvals is expected to provide a lucrative market growth scenario in the region. In addition, the development of health care infrastructure and increased investment to stimulate research activities are expected to boost the Asia Pacific Irritable Bowel Syndrome (IBS) Diagnostics Market over the forecast period.

On the basis of diagnosis, the Irritable Bowel Syndrome (IBS) Diagnosis market has been segmented into Laboratory Tests and Imaging Tests. In 2021, the laboratory testing segment held the largest share of the market, and the same segment is expected to grow at the fastest rate over the next few years. There are no definitive diagnostic tests for detecting irritable bowel syndrome (IBS). Laboratory tests mainly help rule out alternative diagnoses. Patients with IBS are exposed to tests that involve a complete blood count. This helps to confirm the main symptoms of the disease. Laboratory tests check the sample of blood, body tissue, or urine to see if patient results are within the normal range. The Laboratory Testing segment is further sub-segmented into Lactose Intolerance Testing, Breath Testing for Bacterial Overgrowth, Stool Testing and Blood Testing.

Development of Medical Devices for Irritable Bowel Syndrome Diagnosis Fuel Irritable Bowel Syndrome (IBS) Diagnosis Market Growth

The companies are focused on introducing innovative medical devices to diagnose irritable bowel syndrome. These devices are likely to offer superior diagnosis and earlier detection of the disease. Industry players are engaged in the use of chemiluminescent technology to diagnose irritable bowel syndrome. For example, in October 2018, Inova Diagnostics has launched the first FDA-approved calprotectin extraction device with QUANTA Flash Chemiluminescent (CIA) technology that provides reliable results. Semi-quantitative assays offer precise quantification, wide analytical measurement ranges, and fast turnaround time.

Commonwealth Diagnostics International (CDI), Inc. has developed a validated home collection kit for IBSchek to diagnose irritable bowel syndrome. The device is the first clinically validated biomarker blood test for predominantly diarrheal and mixed irritable bowel syndrome (SCI-D, SCI-M) in a new home hair collection kit.

Such devices have the potential to offer excellent diagnostic and operational efficiency over conventional methods. In addition, the adoption of such devices greatly reduces the risk of side effects. Thus, increased research activities, coupled with product innovations, are expected to reshape the irritable bowel syndrome (IBS) diagnostic market in the years to come.

Get Sample Copy of Irritable Bowel Syndrome Diagnostics Market:

Irritable Bowel Syndrome (IBS) Diagnostics Market: Segmental Overview

In terms of indication, the Pain and Cramps segment held the largest share of the market in 2020, and the same segment is expected to register the highest CAGR of 6.5% in the market during the forecast period. . IBS is characterized by abdominal pain and cramps. Patients with IBS may experience stomach cramps or feel that their stools are incomplete. Many people with IBS experience gas and find bloating in their abdomen. After consuming certain foods, the person may experience cramps. Abdominal pain and cramps refer to discomfort felt in the trunk area between the ribs and the pelvis.

The COVID-19 pandemic epidemic at the end of 2019 disrupted various trades and businesses around the world. The approach of the COVID-19 pandemic is expected to open up new opportunities for current players in the IBS diagnostics market landscape. With the spread of the COVID-19 pandemic, it has been discovered that a significant number of people around the world are suffering from irritable bowel syndrome (IBS) such as abdominal pain, cramps or bloating, diarrhea or constipation, and mucus in the stool. because the COVID-19 pandemic has affected people’s psychological health, resulting in higher stress levels. Stress can exaggerate the symptoms of irritable bowel syndrome (IBS). Thus, the impact of COVID-19 is so far considered positive on the market.

Irritable Bowel Syndrome (IBS) Diagnostics Market: Competition Landscape and Key Developments

Commonwealth Diagnostics International; Diagnosis of Genoa; Gemelli Biotech; Prométhée Laboratories; Inova Diagnostics, Inc .; Biohit Oyj; Aerodiagnostics, LLC .; Metabolic Solutions, Inc .; Sysmex Company; and BÜHLMANN Laboratories AG are among the key companies operating in the global irritable bowel syndrome (IBS) diagnostics market. The main players are focused on expanding and diversifying their market presence and acquiring new customers, thereby exploiting existing business opportunities.

Purchase a copy of the Irritable Bowel Syndrome Diagnosis market research report @

In november 2020, Cellesce Ltd. has partnered with Manchester BIOGEL to develop fully synthetic, animal-free three-dimensional (3D) scaffolds that mimic the physiological environment of the human body and enable the manufacture, scaling and improved reproducibility of irritable patient-derived products. diagnosis of bowel syndrome (IBS).

In June 2019, BÃœHLMANN Laboratories AG has received 510 (k) clearance from the US Food and Drug Administration (FDA) for its BÃœHLMANN fCAL turbo. The BÃœHLMANN fCAL turbo is an in vitro diagnostic test for the quantitative measurement of fecal calprotectin (fCAL), a neutrophilic protein which is a marker of inflammation of the intestinal mucosa, in human stool. BÃœHLMANN fCAL turbo helps in the diagnosis of inflammatory bowel disease (IBD) – particularly Crohn’s disease (CD) and ulcerative colitis (UC) – and helps differentiate IBD from irritable bowel syndrome (IBS) by conjunction with other labs and clinics results.

In October 2019, Gemelli Biotech — producer of the ibs-smart blood test for irritable bowel syndrome with a diarrheal component (IBS-D and IBS-M) —announced the formalization of a scientific advisory board to support the company’s expansion on new markets and new offers.

Browse related reports:

About Us:

The Insight Partners is a one-stop-shop for industrial research in actionable intelligence. We help our clients find solutions to their research needs through our syndicated research and advisory services. We specialize in industries such as Semiconductors & Electronics, Aerospace & Defense, Automotive & Transportation, Biotechnology, Health Informatics, Manufacturing & Construction, Medical Devices , technology, media and telecommunications, chemicals and materials.

IIf you have any questions about this report or would like further information, please contact us:

Contact Person: Sameer Joshi
Email: [email protected]
Telephone: + 1-646-491-9876
More research:



Show original content: 4-7-global-covid-19-impact-and-analysis-by-the-insight-partners-301379466.html

SOURCE Insight partners

Comments are closed.